Given the increasing reliance on genetic and biomarker testing (EGFR, ALK, ROS1, PD-L1, and KRAS mutations) for targeted treatments, the ability to perform molecular analysis on minimally invasive samples represents a significant advancement in lung cancer care [2,80,81,82]. This evidence concerns the gene EGFR and lung carcinoma.